Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915585 | 1.00 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13915582 | 0.94 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL14049427 | 0.91 | ADRB3 (0.51) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13927443 | 0.91 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13915583 | 0.90 | ADRB3 (0.59) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13915584 | 0.89 | ADRB3 (0.48) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL14031104 | 0.89 | ADRB3 (0.48) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13915577 | 0.88 | ADRB3 (0.56) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13915581 | 0.86 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL14031114 | 0.85 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCTSBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442695-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | SCHERING CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-7253160-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | DPP3, DPP7, DPP4 | ADRB3 3738/4885ADRA2B 4407/4885ADRA2C 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.